Middle Dose of MRM-3379
Phase 2Small molecule
Middle Dose of MRM-3379 is one of 37 small molecule programs targeting Fragile X Syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Fragile X Syndrome
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Daliresp
AstraZenecaApproved
Namenda
AbbVieApproved
Glucophage
EMD SeronoApproved
Lioresal
NovartisApproved
Rilutek
AAzurity Pharmaceuticals
Approved
Minocin
TTriax
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Middle Dose of MRM-3379. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMirum Pharmaceuticals, Inc.